SEC Filing Analysis: Turn Therapeutics Inc. (TTRX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A key financial executive made a small open-market purchase of common stock.
• Market Impact: The transaction is too small to have a meaningful market impact, representing less than 0.01% of the company's market capitalization.

Company Information

Field	Value
Company	Turn Therapeutics Inc.
Ticker Symbol	TTRX
CIK	0002023016
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Chaudhary Zuraiz
CIK	0002086494
Title/Position	Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-12
Transaction Code	P (Open Market Purchase)
Security Type	Common Stock
Shares Involved	2,500
Price Per Share	$3.50
Total Value	$8,750
Shares Owned After	12,500
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$8,750
% of Market Cap	0.009%
Shares Transacted	2,500
% of Shares Outstanding	Not Available
Post-Transaction Ownership	12,500 shares
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market capitalization of $100 million, this $8,750 transaction is financially immaterial to the company.
• Transaction Significance: The purchase is considered to have low significance due to its negligible size relative to the company's market cap, despite being an open-market buy by a high-ranking officer.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction value is too small to signal a significant shift in insider confidence or to influence market sentiment.

Volume & Sentiment

• Expected Volume Impact: Minimal. The trade size is unlikely to affect trading volume.
• Sentiment Indicator: Neutral. While an insider purchase is technically a bullish event, the insignificant size of this trade neutralizes its impact on sentiment.